Literature DB >> 20936888

Catechin inhibits adhesion and migration of peripheral blood B cells by blocking CD11b.

Kazushige Kawai1, Nelson H Tsuno, Joji Kitayama, Eiji Sunami, Koki Takahashi, Hirokazu Nagawa.   

Abstract

CONTEXT: Previously, we demonstrated that CD11b is expressed on peripheral blood memory B cells, and it plays an important role in the migration of B cells. And epigallocatechin gallate (EGCG), a bioactive component of green tea, by binding to CD11b, expressed on CD8(+) cytotoxic T cells, inhibited their migratory ability, one possible mechanism of the antiallergic activity of EGCG.
OBJECTIVE: Here, we investigated whether EGCG also affected CD11b expressed on B cells, similar to cytotoxic T cells.
MATERIALS AND METHODS: Isolated peripheral blood CD19(+) B cells were treated with EGCG and the change in the expression of CD11b was analyzed using flow cytometry. The effects of EGCG on the ability of B cells to adhere to and to transmigrate through the endothelial cell layer were evaluated using the transwell assay.
RESULTS: EGCG significantly suppressed the apparent expression of CD11b on B cells, in the flow-cytometric analysis, and this apparent suppression was speculated to be dependent on the competitive binding of EGCG to CD11b. EGCG also significantly suppressed CD11b-mediated migration and adhesion of B cells to endothelial cells. DISCUSSION AND
CONCLUSION: EGCG has a strong suppressive activity on the adhesive and migratory abilities of peripheral blood B cells. This suppressive activity was mediated by the binding of EGCG to CD11b on B cells, and the consequent suppression of B-cell extravasation to the extravascular space. Because B cell plays an important role in the humoral immunity, EGCG could be a promising drug for the prevention and/or treatment of allergic and/or autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20936888     DOI: 10.3109/08923973.2010.522195

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  6 in total

1.  Epigallocatechin-3-gallate ameliorates experimental autoimmune encephalomyelitis by altering balance among CD4+ T-cell subsets.

Authors:  Junpeng Wang; Zhihong Ren; Yanmei Xu; Sheng Xiao; Simin N Meydani; Dayong Wu
Journal:  Am J Pathol       Date:  2011-11-03       Impact factor: 4.307

2.  Polyphenol Supplementation Reverses Age-Related Changes in Microglial Signaling Cascades.

Authors:  Ahmad Jalloh; Antwoine Flowers; Charles Hudson; Dale Chaput; Jennifer Guergues; Stanley M Stevens; Paula C Bickford
Journal:  Int J Mol Sci       Date:  2021-06-14       Impact factor: 5.923

3.  Activated Human Memory B Lymphocytes Use CR4 (CD11c/CD18) for Adhesion, Migration, and Proliferation.

Authors:  Zsuzsa Nagy-Baló; Richárd Kiss; Alina Menge; Csaba Bödör; Zsuzsa Bajtay; Anna Erdei
Journal:  Front Immunol       Date:  2020-09-29       Impact factor: 7.561

Review 4.  Immunomodulatory Effects of Dietary Polyphenols.

Authors:  Hira Shakoor; Jack Feehan; Vasso Apostolopoulos; Carine Platat; Ayesha Salem Al Dhaheri; Habiba I Ali; Leila Cheikh Ismail; Marijan Bosevski; Lily Stojanovska
Journal:  Nutrients       Date:  2021-02-25       Impact factor: 5.717

5.  Randomized, double-blind, placebo-controlled clinical trial measuring the effect of a dietetic food on dermatologic scoring and pruritus in dogs with atopic dermatitis.

Authors:  Miguel Sánchez de Santiago; José Luis González Arribas; Yolanda Moral Llamas; Iveta Becvarova; Hein Meyer
Journal:  BMC Vet Res       Date:  2021-11-19       Impact factor: 2.741

6.  Randomized double-blind clinical study in patients with COVID-19 to evaluate the safety and efficacy of a phytomedicine (P2Et).

Authors:  Claudia Urueña; Ricardo Ballesteros-Ramírez; Alejandra Gomez-Cadena; Alfonso Barreto; Karol Prieto; Sandra Quijano; Pablo Aschner; Carlos Martínez; Maria I Zapata-Cardona; Hajar El-Ahanidi; Camilla Jandus; Lizdany Florez-Alvarez; Maria Teresa Rugeles; Wildeman Zapata-Builes; Angel Alberto Garcia; Susana Fiorentino
Journal:  Front Med (Lausanne)       Date:  2022-09-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.